Perspectives on designs of antiandrogens for prostate cancer

Author： EstÉbanez-PerpiñÁ Eva   Jouravel Natalia   Fletterick Robert J  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.2, Iss.10, 2007-10, pp. : 1341-1355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tolerability of Antiandrogens in the Treatment of Prostate Cancer

By Fourcade R.-O.   McLeod D.  

UroOncology, Vol. 4, Iss. 1, 2004-03 ,pp. : 5-13

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Antiandrogens in Prostate Cancer Endocrine Therapy

By  

Current Cancer Drug Targets, Vol. 4, Iss. 5, 2004-08 ,pp. : 455-461

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer

By Mahler C.   Verhelst J.   Denis L.  

Clinical Pharmacokinetics, Vol. 34, Iss. 5, 1998-05 ,pp. : 405-417

Adis International

Access to resources Recommend Favorite

Do antiandrogens improve survival in prostate cancer?

By  

Inpharma, Vol. 1, Iss. 1236, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Non-steroidal anti-androgens in prostate cancer - current treatment practice

By Han M.   Nelson J.B.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 443-449

Informa Healthcare

Access to resources Recommend Favorite